Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion

The biotech drugmaker has a market value of roughly $10 billion, meaning that Gilead would be paying up for the company and its prized breast-cancer drug.

The post Gilead Nears Deal to Buy Immunomedics for More Than Billion first appeared on Online Web Store Site.